Research interests, current research projects and the Edinburgh Tommy's Centre.
My research work focusses on the pregnancy “stressors” of maternal depression/stress, inflammation and hypoxia. These pregnancy stressors are largely responsible for the clinical conditions of gestational diabetes, preterm birth and stillbirth, all of which have devastating effects on pregnant women and their babies. My group aims to understand how these pregnancy stressors cause these clinical conditions and to develop preventive and therapeutic strategies. In all our research endeavours, we use a broad array of research strategies, from basic science, through animal models, to clinical trials and beyond to population based research to address these clinical problems.
Professor Jane Norman is Director of the Edinburgh Tommy's Centre which is funded by the charity Tommy's. Opened in May 2008 it is located within the MRC Centre for Reproductive Health. The Tommy’s Centre aims to conduct world class research that will have a direct impact on the health of pregnant women and their babies and to translate our research into improved health outcomes both locally and worldwide.
2008 – 2015
Norman JE et al. Does progesterone prophylaxis to prevent preterm labour improve outcome- a randomised double blind placebo controlled trial? (OPPTIMUM). £2,700,000
2008 – 2016
Norman JE, Calder AA, Denison F, Reynolds R, Forbes S. Core funding for Edinburgh Tommy’s Centre for Maternal and Fetal Health. Tommy’s the baby charity. £3,040,000
2011 - 2016
Saunders P, Anderson R, Critchley H, Norman JE, Iredale J, Forbes S, Seckl J. Core support for the MRC Centre for Reproductive Health. £1,100,000
Gray N, Norman JE, Girardi G, Granneman S. Poly(A)-binding proteins highlight the importance of regulated mRNA translation and stability in determining a functional materno-fetal interface. MRC Programme Grant. £1,494,491
2013 - 2016
Norman JE, Calderwood C, Cunningham Burley S, Scott J, Weir C, Chalmers J, Murdoch E, Stock SJ, Ross-Davie M, McAuliffe F, Geary M, Hunter AJ, Heazell A, Froen F. Does promoting increased awareness of decreased fetal movements reduce stillbirth, a stepped wedge cluster randomised trial? Chief Scientist Office, Scottish Executive, (HSRC), Tommy's and Sands. £330,000.
2014 - 2016
Norman JE, Denison FC, Reynolds R, Alexander C, Love C, Pennycard J, Strachan M, Linsday R, Mackenzie F, Juszczak E, Stenson B. Glibenclamide and metfoRmin versus stAndard Care in gEstational diabeteS (GRACES) – a feasibility open label randomised trial. Chief Scientist Office, Scottish Executive. £217,384
2014 - 2018
Norman JE, Shennan A, Robson S, Norrie J, Thornton S, Kilby M, Marlow N, Stock S, Smith J, Denton J, Bennett P, Cunningham Burley S. An open randomised trial of the Arabin pessary to prevent preterm birth in twin pregnancy - STOPPIT- 2. National Institute of Health, Health Technology Assessment Board. £1,327,029.
Ismail K, Toozs-Hobson P, Slack M, Ewer A, Gray J, Scott J, Israfil-Bayli F, Fleming L, Shennan A, Norman JE, Daniels J, Lees C, Middleton L, Simpson N. Suture Type for Incompetent Cervix and effect on Health outcomes. National Institute of Health, Health Technology Assessment Board. £1,090,069
Tarnow-Mordi W, Dibley M, Norman JE, Reynolds R, Callander E. Should we treat iron deficiency anaemia of pregnancy with lactoferrin? A randomised controlled trial. NHMRC (Australia). $ (AUD) 2,050,000
Coomarasamy A, Bourne T, Horne A, Norman JE, Jurkovic D, Farquharson R, Lumsden MA, Overton C, Roberts T, Harb H, Bender Atik R, Daniels J, Raine-Fening N, Quenby S, Middleton L, Gupta P Hinshaw K. Effectiveness of progesterone to prevent miscarriage in women with early pregnancy bleeding: A randomised placebo-controlled trial (PRISM Trial: PRogesterone In Spontaneous Miscarriage Trial). National Institute of Health, Health Technology Assessment Board.£1,756,618.
Denison FC, Norman JE, Norrie J, Scotland G, McPherson G, Lawton J, Brook-Smith S, Peace M, Clinton J, Clarkson C. A pragmatic adaptive sequential placebo controlled randomised trial to determine the effectiveness of Glycerin trinitrate for retained placenta (Got-it trial). National Institute of Health, Health Technology Assessment Board. £1,712,125
Flenady V, Gardener G, Middleton P, Coory M, Ellwood D, Crowther C, East C, Callander E, Norman JE, Boyle F. My baby’s movements. NHMRC (Australia) $ (AUD) 1,364,274
Vice-Principal People and Culture
Director of the Tommy’s Centre for Maternal and Fetal Health CRH lead for “Theme 3” of the Centre for Reproductive Health: Theme 3 “Developmental programming by steroid hormones and reproductive resilience”
1. Journal editorships Molecular Human Reproduction, Associate Editor (2012 -2015)
2. Grant awarding committees CSO Health Services Research 2012 onwards GAPPs Preventing Preterm Birth Initiative, 2012 onwards
3. Membership of research consortia Deputy Lead, Reproductive Health and Childbirth Specialty Research Group (Scotland), 2012 onwards Global Obstetric Network (GONET) 2010 onwards, Vice Chair since 2013
4. Work for specialist societies Executive committee, British Maternal and Fetal Medicine Society, 2010 onwards Member of Council, Society for Gynecologic Investigation, 2011 onwards Member of Council, Academy of Medical Sciences, 2015 onwards
5. Trial management committees Member of Data Monitoring Committee, INFANT study [Intelligent Fetal Monitoring and Assessment] HTA funded 2009 onwards Chair of Trial Steering Committee, EME funded Tablet study, 2011 onwards Chair of Trial Steering Committee for Phoenix study (HTA funded) 2014 onwards
6. Other Member of the NETSCC, Health Technology Assessment programme – Maternal, Neonatal and Child Health Panel, 2013 onwards Member, National Perinatal Epidemiology Unit Clinical Trials Advisory Group, 2012 onwards Chair, NICE Guideline Development Group, Preterm labour and birth, 2012 onwards Member, Stillbirth Subgroup, Child and Maternal Health Division of the Scottish Government Health and Social Care Directorates, 2011 onwards Chair, Technical Advisory Group for Reproductive and Sexual health section of the International Classification of Disease, World Health Organisation), 2010 onwards Board Member, Equality Challenge Unit, 2015 onwards